Successful Up-front Combination Therapy in a Patient With Idiopathic Pulmonary Hypertension and Patent Foramen Ovale: An Alternative to Epoprostenol Therapy?

被引：8

作者：

Pitsiou, Georgia G. ^{[1
]}

Chavouzis, Nikolaos ^{[1
]}

Nakou, Chrysanthi ^{[1
]}

Boutou, Afroditi K. ^{[1
]}

Argyropoulou, Paraskevi ^{[1
]}

Stanopoulos, Ioannis ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Resp Failure Unit, G Papanikolaou Hosp, Thessaloniki 57010, Greece

来源：

JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2009年 / 28卷 / 06期

关键词：

ORAL SILDENAFIL;

D O I：

10.1016/j.healun.2009.03.009

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Pulmonary arterial hypertension (PAH) is a life-threatening disease of the pulmonary arterioles, which, in the absence of effective therapy, progresses rapidly to right heart failure and death. Opening of a patent foramen ovale (PFO) is common in patients with severe pulmonary hypertension (PH), resulting in resistive hypoxemia. We report the case of a 40-year-old woman with idiopathic pulmonary hypertension (iPAH) in New York Heart Association (NYHA) class Ill to IV, who was admitted in the intensive care unit with hemodynamic compromise and severe hypoxemia due to right-to-left shunt throughout a PFO. Combination therapy initially with inhaled iloprost and sildenafil, and then addition of an endothelin A receptor-selective antagonist (sitaxsentan), resulted in impressive improvement in oxygenation with reversal of the right-to-left shunt and marked improvement in functional class of the patient. J Heart Lung Transplant 2009;28:651-3. Copyright (C) 2009 by the International Society for Heart mid Lung Transplantation.

引用

页码：651 / 653

页数：3

共 9 条

[1]

Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].